title: Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034.
abstract: OBJECTIVE
  Diffuse large B-cell lymphoma (DLBCL) represents a clinically heterogeneous disease. Models based on immunohistochemistry predict clinical outcome. These include subdivision into germinal center (GC) versus non-GC subtypes; proliferation index (measured by expression of Ki-67), and expression of BCL-2, FOXP1, or B-lymphocyte-induced maturation protein (Blimp-1)/PRDM1. We sought to determine whether immunohistochemical analyses of biopsies from patients with DLBCL having HIV infection are similarly relevant for prognosis.
  
  
  METHODS
  We examined 81 DLBCLs from patients with AIDS in AMC010 (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP] v CHOP-rituximab) and AMC034 (etoposide, doxorubicin, vincristine, prednisone, and dose-adjusted cyclophosphamide plus rituximab concurrent v sequential) clinical trials and compared the immunophenotype with survival data, Epstein-Barr virus (EBV) positivity, and CD4 counts.
  
  
  RESULTS
  The GC and non-GC subtypes of DLBCL did not differ significantly with respect to overall survival or CD4 count at cancer presentation. EBV could be found in both subtypes of DLBCL, although less frequently in the GC subtype, and did not affect survival. Expression of FOXP1, Blimp-1/PRDM1, or BCL-2 was not correlated with the outcome in patients with AIDS-related DLBCL.
  
  
  CONCLUSIONS
  These data indicate that with current treatment strategies for lymphoma and control of HIV infection, commonly used immunohistochemical markers may not be clinically relevant in HIV-infected patients with DLBCL. The only predictive immunohistochemical marker was found to be Ki-67, where a higher proliferation index was associated with better survival, suggesting a better response to therapy in patients whose tumors had higher proliferation rates.
authors.affiliation: Weill Cornell Medical College, New York, NY 10065, USA.
authors.forename: Amy
authors.initials: A
authors.lastname: Chadburn
authors.forename: April
authors.initials: A
authors.lastname: Chiu
authors.forename: Jeannette Y
authors.initials: JY
authors.lastname: Lee
authors.forename: Xia
authors.initials: X
authors.lastname: Chen
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hyjek
authors.forename: Alison H
authors.initials: AH
authors.lastname: Banham
authors.forename: Ariela
authors.initials: A
authors.lastname: Noy
authors.forename: Lawrence D
authors.initials: LD
authors.lastname: Kaplan
authors.forename: Joseph A
authors.initials: JA
authors.lastname: Sparano
authors.forename: Kishor
authors.initials: K
authors.lastname: Bhatia
authors.forename: Ethel
authors.initials: E
authors.lastname: Cesarman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D049109:Cell Proliferation; D006801:Humans; D007150:Immunohistochemistry; D016130:Immunophenotyping; D019394:Ki-67 Antigen; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy / Q000276:immunology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000276:immunology*; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D019394:Ki-67 Antigen